Latest Safety News

Anteris Technologies has secured FDA approval to commence its pivotal PARADIGM clinical trial, testing its innovative DurAVR Transcatheter Heart Valve against established devices in patients with severe aortic stenosis.

Bioxyne Limited, through its subsidiary Breathe Life Sciences, has inked an exclusive deal to import, manufacture, and distribute Curaleaf’s Que Medical Inhalation Device in Australia, with a nationwide launch set for November 2025.

Tryptamine Therapeutics has initiated the world’s first clinical trial of its IV-infused psilocin drug, TRP-8803, targeting Binge Eating Disorder, alongside a pioneering EEG biomarker collaboration and new funding.

Vertex Minerals has commenced underground ore production at its Reward Gold Mine in New South Wales, processing high-grade ore through a gravity-only plant with strong recoveries. The company also advanced its A$11 million capital raising, positioning itself for steady growth into 2026.

EMU NL has sold its Badja Gold Project for over A$3.5 million, retired all debt, and is set to commence a maiden drilling program at its Yataga Copper Project in Queensland, fully funded and under new board leadership.

InhaleRx has secured FDA alignment and ethics approvals to progress clinical trials for its inhaled therapies targeting breakthrough cancer pain and panic disorder, with patient dosing set to begin soon.

Recce Pharmaceuticals has commenced patient dosing in its pivotal Phase 3 trial for diabetic foot infections in Indonesia, supported by promising antibacterial efficacy data and extended funding arrangements.

Cyclone Metals advances its flagship Iron Bear Project despite a minor delay in drilling caused by First Nations election disputes, while strengthening its cash position through significant share sales.

DGR Global Limited’s Q3 2025 report reveals ongoing project development, strategic equity holdings, and complex legal proceedings shaping its resource company creation model.

Atlantic Lithium has finalized revised fiscal terms with the Ghanaian government for its Ewoyaa Lithium Project and awaits parliamentary ratification, while reporting strong exploration results in Côte d’Ivoire and securing significant funding agreements.

Chimeric Therapeutics has progressed its CHM CDH17 and CHM CORE-NK clinical trials with promising safety and efficacy signals, while securing a key manufacturing partnership and appointing a renowned haematologist to its board. However, the company faces a pressing cash runway challenge.

Botala Energy has made significant strides in developing its Serowe coal bed methane project in Botswana, securing a $1.5 million placement and government interest to address Southern Africa’s looming gas shortage.